This prospective, observational, open-label, multi-center, single-arm, post-approval study is designed to evaluate the continued safety and effectiveness of the XIENCE PRIME EECSS in a cohort of real-world patients receiving the XIENCE PRIME EECSS during commercial use in real-world settings in China.

This study has no primary outcome measure. All observations are of equal weight.

Cohort of real-world patients receiving the XIENCE PRIME EECSS during commercial use in realworld settings in China.

Criteria

Inclusion Criteria:

The patient must be at least 18 years of age at the time of signing the informed consent.

The patient or his/her legally-authorized representative signs the EC-approved Informed Consent Form (ICF).

Only XIENCE PRIME stent(s) is (are) implanted during the index procedure.

Exclusion Criteria:

No other exclusion criteria are specified for this study.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01894152